A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).

Authors

Edith A. Perez

Mayo Clinic, Jacksonville, FL

Edith A. Perez , Jose Manuel Lopez-Vega , Lucia Del Mastro , Thierry Petit , Lada Mitchell , Christina H. Pelizon , Michael Andersson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.

First Author: Nicholas Patrick McAndrew

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).

First Author: Kazutaka Narui

insert_chart_outlined

Poster

2012 Breast Cancer Symposium

bookmark_border

Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).

First Author: Farrah Datko

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).

First Author: Farrah Mikhail Datko